Published in Br J Haematol on August 16, 2011
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease | NCT00530270
Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Pediatr Blood Cancer (2013) 0.91
Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial. Pediatr Blood Cancer (2014) 0.90
Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov. Clin Trials (2015) 0.89
Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am (2013) 0.89
Inflammatory targets of therapy in sickle cell disease. Transl Res (2015) 0.80
Advances in sickle cell therapies in the hydroxyurea era. Mol Med (2014) 0.80
Simulation of various randomization strategies for a clinical trial in sickle cell disease. Hematology (2016) 0.76
Asthma management in sickle cell disease. Biomed Res Int (2013) 0.75
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med (1994) 3.10
Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood (1997) 2.74
A treatment allocation procedure for sequential clinical trials. Biometrics (1980) 2.26
Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet (2003) 2.15
Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood (1998) 1.79
Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood (1998) 1.57
Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood (1999) 1.25
The intriguing contribution of white blood cells to sickle cell disease - a red cell disorder. Blood Rev (2004) 1.19
Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. Br J Haematol (2009) 1.00
Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res (2008) 0.96
A recommitment to sickle cell disease research. Blood (2008) 0.93
A short course of prednisone in the management of acute chest syndrome of sickle cell disease. J Pediatr Hematol Oncol (2010) 0.82
A single-institution experience with treatment of severe acute chest syndrome: lack of rebound pain with dexamethasone plus transfusion therapy. J Pediatr Hematol Oncol (2008) 0.82
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med (2007) 6.76
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Improved survival of children and adolescents with sickle cell disease. Blood (2010) 3.30
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med (2003) 2.93
Survival of children with sickle cell disease. Blood (2004) 2.84
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol (2007) 2.70
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med (2006) 2.67
Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2007) 2.60
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood (2013) 2.41
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer (2010) 2.36
Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) (2008) 2.28
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA (2010) 2.25
A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr (2003) 2.24
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood (2008) 2.17
Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet (2003) 2.15
Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol (2005) 2.10
Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood (2005) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family. J Lipid Res (2004) 2.08
Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol (2006) 2.06
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood (2002) 2.02
Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med (2004) 2.01
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr (2003) 2.00
Tropomodulin 1-null mice have a mild spherocytic elliptocytosis with appearance of tropomodulin 3 in red blood cells and disruption of the membrane skeleton. Blood (2010) 1.99
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
Sickle cell trait and the risk of venous thromboembolism among blacks. Blood (2007) 1.95
Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol (2006) 1.89
Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr (2007) 1.89
Vascular complications after splenectomy for hematologic disorders. Blood (2009) 1.89
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood (2011) 1.85
Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg (2007) 1.83
Enhanced pulmonary and systemic response to endotoxin in transgenic sickle mice. Am J Respir Crit Care Med (2003) 1.82
Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood (2004) 1.82
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med (2008) 1.79
Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.75
High variation between hospitals in vena cava filter use for venous thromboembolism. JAMA Intern Med (2013) 1.72
Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med (2008) 1.69
Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood (2012) 1.66
Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program (2007) 1.65
Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol (2005) 1.64
Medical care utilization and mortality in sickle cell disease: a population-based study. Am J Hematol (2005) 1.61
Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.60
D-dimer antigen: current concepts and future prospects. Blood (2008) 1.59
Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol (2004) 1.58
Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer (2010) 1.53
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood (2014) 1.53
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood (2002) 1.52
Silent infarcts in young children with sickle cell disease. Br J Haematol (2009) 1.51
Human term placenta as a source of hematopoietic cells. Exp Biol Med (Maywood) (2009) 1.51
Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr (2002) 1.50
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A (2007) 1.48
Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer (2008) 1.47
Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood (2002) 1.47
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant (2009) 1.46
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res (2009) 1.43
Major burn injury is not associated with acute traumatic coagulopathy. J Trauma Acute Care Surg (2013) 1.43
Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood (2007) 1.43
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood (2011) 1.43
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr (2010) 1.43
Venous thromboembolism in ovarian cancer. Gynecol Oncol (2007) 1.42
Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. Pediatr Blood Cancer (2013) 1.42
Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study. Blood (2002) 1.40
Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy. J Pediatr Hematol Oncol (2002) 1.40
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol (2007) 1.39
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood (2005) 1.37
Burden of diagnostic radiation exposure in children with sickle cell disease. Pediatr Blood Cancer (2014) 1.37
Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica (2009) 1.36
Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2005) 1.35
Mammalian acyl-CoA:lysophosphatidylcholine acyltransferase enzymes. Proc Natl Acad Sci U S A (2007) 1.33
Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer (2010) 1.33
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood (2006) 1.31
A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom (2009) 1.31
Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol (2006) 1.31
Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer (2008) 1.30
Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials (2011) 1.28
Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood (2008) 1.28
Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol (2014) 1.27
Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies. Am J Geriatr Psychiatry (2010) 1.27
Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood (2011) 1.26
Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood (2003) 1.25
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol (2010) 1.25